期刊文献+

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations 被引量:6

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations
下载PDF
导出
摘要 AIM: To determine the mutation status of human telomerase reverse transcriptase gene(TERT) promoter region in hepatocellular carcinoma(HCC) from different geographical regions.METHODS: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors,collected from patients living in Asia,Europe and Africa.We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR.Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference.RESULTS: The TERT mutations were found highly frequent in HCC.Eight of the fifteen tested cell lines displayed C228 T mutation,and one had C250 T mutation with a mutation frequency up to 60%.All of the mutations were heterozygous and mutually exclusive.Ten out of forty-four tumors displayed C228 T mutation,and additional five tumors had C250 T mutation providing evidence for mutation frequency of 34% in primary tumors.Considering the geographic origins of HCC tumors tested,TERT promoter mutation frequencies were higher in African(53%),when compared to non-African(24%) tumors(P = 0.056).There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism(P = 0.058).Mutation frequency was nearly two times higher in established HCC celllines(60%) compared to the primary tumors(34%).CONCLUSION: TERT promoter is one of most frequent mutational targets in liver cancer,and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control. AIM: To determine the mutation status of human telomerase reverse transcriptase gene(TERT) promoter region in hepatocellular carcinoma(HCC) from different geographical regions.METHODS: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors,collected from patients living in Asia,Europe and Africa.We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR.Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference.RESULTS: The TERT mutations were found highly frequent in HCC.Eight of the fifteen tested cell lines displayed C228 T mutation,and one had C250 T mutation with a mutation frequency up to 60%.All of the mutations were heterozygous and mutually exclusive.Ten out of forty-four tumors displayed C228 T mutation,and additional five tumors had C250 T mutation providing evidence for mutation frequency of 34% in primary tumors.Considering the geographic origins of HCC tumors tested,TERT promoter mutation frequencies were higher in African(53%),when compared to non-African(24%) tumors(P = 0.056).There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism(P = 0.058).Mutation frequency was nearly two times higher in established HCC celllines(60%) compared to the primary tumors(34%).CONCLUSION: TERT promoter is one of most frequent mutational targets in liver cancer,and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第1期311-317,共7页 世界胃肠病学杂志(英文版)
基金 Supported by TUBITAK,the Scientific and Technological Research Council of Turkey,No.113S389 TUBITAK(BIDEB-2211) TUBITAK(BIDEB-2211 and BIDEB-2214) EMBO short term fellowships
关键词 HEPATOCELLULAR CARCINOMA Liver cancer TELOMERASE r Hepatocellular carcinoma Liver cancer Telomerase r
  • 相关文献

参考文献18

  • 1Naosuke Nonoguchi,Takashi Ohta,Ji-Eun Oh,Young-Ho Kim,Paul Kleihues,Hiroko Ohgaki.TERT promoter mutations in primary and secondary glioblastomas[J]. Acta Neuropathologica . 2013 (6)
  • 2I?igo Landa,Ian Ganly,Timothy A. Chan,Norisato Mitsutake,Michiko Matsuse,Tihana Ibrahimpasic,Ronald A. Ghossein,James A. Fagin.Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease[J]. The Journal of Clinical Endocrinology & Metabolism . 2013 (9)
  • 3Cigdem Ozen,Gokhan Yildiz,Alper Tunga Dagcan,Dilek Cevik,Aysegul Ors,Umur Keles,Hande Topel,Mehmet Ozturk.Genetics and epigenetics of liver cancer[J].New BIOTECHNOLOGY.2013(4)
  • 4Bruno Bernardes de Jesus,Maria A. Blasco.Telomerase at the intersection of cancer and aging[J]. Trends in Genetics . 2013
  • 5Carol W. Greider.Wnt Regulates TERT—Putting the Horse Before the Cart[J]. Science . 2012 (6088)
  • 6Katrin Hoffmeyer,Angelo Raggioli,Stefan Rudloff,Roman Anton,Andreas Hierholzer,Ignacio Del Valle,Kerstin Hein,Riana Vogt,Rolf Kemler.Wnt/β-Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells[J]. Science . 2012 (6088)
  • 7Franziska van Zijl,Gudrun Zulehner,Michaela Petz,Doris Schneller,Christoph Kornauth,Mara Hau,Georg Machat,Markus Grubinger,Heidemarie Huber,Wolfgang Mikulits.Epithelial–mesenchymal transition in hepatocellular carcinoma[J]. Future Oncol. . 2009 (8)
  • 8Mehmet Ozturk,Ayca Arslan-Ergul,Sevgi Bagislar,Serif Senturk,Haluk Yuzugullu.Senescence and immortality in hepatocellular carcinoma[J]. Cancer Letters . 2008 (1)
  • 9Shibo Lin,Katrin Hoffmann,Peter Schemmer.Treatment of Hepatocellular Carcinoma:A Systematic Review. Liver Cancer . 2012
  • 10Venook Alan P,Papandreou Christos,Furuse Junji,de Guevara Laura Ladrón.The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncologist . 2010

共引文献9

同被引文献36

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部